Skip to main content

06.12.2024 | Original Research Article

Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities

verfasst von: Hossein Ameri, Thomas G. Poder

Erschienen in: Applied Health Economics and Health Policy

Einloggen, um Zugang zu erhalten

Abstract

Background

The dead state can affect the value sets derived from discrete choice experiments (DCEs). Our aim was to empirically assess the direct impact of the immediate death state on health utilities using discrete choice experiment with time (DCETTO).

Methods

A sample of the general population in Quebec, Canada, completed two approaches: DCETTO followed by a best-worst scaling with time (BWSTTO) (hereafter referred to as DCEBWS), versus DCETTO followed by the dominated option and the immediate death state (hereafter referred to as DCEDOD), both designed with the SF-6Dv2. In DCEBWS, all participants first completed 10 DCETTO choices (i.e., option A vs B), followed by 3 BWSTTO. In DCEDOD, the same participants first completed the same 10 DCETTO choices, followed by a repeated choice between the dominated option (i.e., A or B) and the immediate death state. A conditional logit model was used to estimate value sets. The performance of models was assessed using goodness of fit using Bayesian information criterion, parameters’ logical consistency, and levels’ significance. The direct impact of the death state on DCE latent utilities was evaluated by examining the magnitude of coefficients, assessing the agreement among the value sets estimated by DCETTO with DCEBWS and with DCEDOD using Bland-Altman plots, the proportion of worst-than-dead (WTD) health states, and analyzing the range of estimated values.

Results

From 398 participants, a total of 348 participants were included for final analysis. The number of parameters with illogical consistency and non-significant coefficients was lower in DCEBWS. The observed consistency in the relative importance of dimensions across all approaches suggests a stable and reliable ranking. The utility range for DCEDOD (− 0.921 to 1) was narrower than for DCETTO (− 1.578 to 1) and DCEBWS (− 1.150 to 1). The DCEDOD estimated a lower percentage of WTD health states (20.01 %) compared to DCETTO (47.19 %) and DCEBWS (33.73 %). The agreement between DCETTO and DCEBWS was slightly stronger than between DCETTO and DCEDOD, and the mean utility values were higher in DCEDOD than in DCEBWS.

Conclusions

The inclusion of the immediate death state directly within DCE increased utility values. This increase was higher when the immediate death was included in a sequence within a DCETTO (i.e., DCEDOD) than when it was included in a continuum of DCETTO (i.e., DCEBWS). The use of DCEDOD was potentially better suited to incorporate the dead state into a DCE.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
4.
Zurück zum Zitat Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed
5.
Zurück zum Zitat Brazier J, Ratcliffe J, Saloman J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2017. Brazier J, Ratcliffe J, Saloman J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2017.
6.
Zurück zum Zitat Brazier J, Rowen D, Yang Y, Tsuchiya A. Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. Eur J Health Econ. 2012;13:575–87.CrossRefPubMed Brazier J, Rowen D, Yang Y, Tsuchiya A. Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. Eur J Health Econ. 2012;13:575–87.CrossRefPubMed
7.
Zurück zum Zitat Wang H, Rowen DL, Brazier JE, Jiang L. Discrete choice experiments in health state valuation: a systematic review of progress and new trends. Appl Health Econ Health Policy. 2023;21(3):405–18.CrossRefPubMedPubMedCentral Wang H, Rowen DL, Brazier JE, Jiang L. Discrete choice experiments in health state valuation: a systematic review of progress and new trends. Appl Health Econ Health Policy. 2023;21(3):405–18.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Lancaster KJ. A new approach to consumer theory. J Polit Econ. 1966;74(2):132–57.CrossRef Lancaster KJ. A new approach to consumer theory. J Polit Econ. 1966;74(2):132–57.CrossRef
9.
Zurück zum Zitat Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171–89.CrossRefPubMed Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171–89.CrossRefPubMed
10.
Zurück zum Zitat McIntosh E, Louviere J, editors. Separating weight and scale value: an exploration of best-attribute scaling in health economics. In: Health Economists' Study Group meeting; 2002. McIntosh E, Louviere J, editors. Separating weight and scale value: an exploration of best-attribute scaling in health economics. In: Health Economists' Study Group meeting; 2002.
11.
Zurück zum Zitat Norman R, Cronin P, Viney R. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states. Appl Health Econ Health Policy. 2013;11:287–98.CrossRefPubMed Norman R, Cronin P, Viney R. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states. Appl Health Econ Health Policy. 2013;11:287–98.CrossRefPubMed
12.
Zurück zum Zitat Norman R, Mulhern B, Lancsar E, Lorgelly P, Ratcliffe J, Street D, Viney R. The use of a discrete choice experiment including both duration and dead for the development of an EQ-5D-5L value set for Australia. Pharmacoeconomics. 2023;41(4):427–38.CrossRefPubMedPubMedCentral Norman R, Mulhern B, Lancsar E, Lorgelly P, Ratcliffe J, Street D, Viney R. The use of a discrete choice experiment including both duration and dead for the development of an EQ-5D-5L value set for Australia. Pharmacoeconomics. 2023;41(4):427–38.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Viney R, Norman R, Brazier J, Cronin P, King MT, Ratcliffe J, Street D. An Australian discrete choice experiment to value EQ-5D health states. Health Econ. 2014;23(6):729–42.CrossRefPubMed Viney R, Norman R, Brazier J, Cronin P, King MT, Ratcliffe J, Street D. An Australian discrete choice experiment to value EQ-5D health states. Health Econ. 2014;23(6):729–42.CrossRefPubMed
14.
Zurück zum Zitat Mulhern BJ, Bansback N, Norman R, Brazier J. Valuing the SF-6Dv2 classification system in the United Kingdom using a discrete-choice experiment with duration. Med Care. 2020;58(6):566–73.CrossRefPubMed Mulhern BJ, Bansback N, Norman R, Brazier J. Valuing the SF-6Dv2 classification system in the United Kingdom using a discrete-choice experiment with duration. Med Care. 2020;58(6):566–73.CrossRefPubMed
15.
Zurück zum Zitat Mulhern B, Norman R, Brazier J. Valuing SF-6Dv2 in Australia using an international protocol. Pharmacoeconomics. 2021;39:1151–62.CrossRefPubMed Mulhern B, Norman R, Brazier J. Valuing SF-6Dv2 in Australia using an international protocol. Pharmacoeconomics. 2021;39:1151–62.CrossRefPubMed
16.
Zurück zum Zitat Poder TG, Carrier N, Kouakou CR. Quebec health-related quality-of-life population norms using the EQ-5D-5L: decomposition by sociodemographic data and health problems. Value Health. 2020;23(2):251–9.CrossRefPubMed Poder TG, Carrier N, Kouakou CR. Quebec health-related quality-of-life population norms using the EQ-5D-5L: decomposition by sociodemographic data and health problems. Value Health. 2020;23(2):251–9.CrossRefPubMed
17.
Zurück zum Zitat Dufresne É, Poder TG, Samaan K, Lacombe-Barrios J, Paradis L, Des Roches A, Bégin P. SF-6Dv2 preference value set for health utility in food allergy. Allergy. 2021;76(1):326–38.CrossRefPubMed Dufresne É, Poder TG, Samaan K, Lacombe-Barrios J, Paradis L, Des Roches A, Bégin P. SF-6Dv2 preference value set for health utility in food allergy. Allergy. 2021;76(1):326–38.CrossRefPubMed
18.
Zurück zum Zitat Wu J, Xie S, He X, Chen G, Bai G, Feng D, Hu M, Jiang J, et al. Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension. Pharmacoeconomics. 2021;39:521–35.CrossRefPubMedPubMedCentral Wu J, Xie S, He X, Chen G, Bai G, Feng D, Hu M, Jiang J, et al. Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension. Pharmacoeconomics. 2021;39:521–35.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Ameri H, Poder TG. Valuing SF 6Dv2 using a discrete choice experiment in a general population in Quebec, Canada. Int J Health Policy Manag. 2024;13(1):1–12.CrossRefPubMedPubMedCentral Ameri H, Poder TG. Valuing SF 6Dv2 using a discrete choice experiment in a general population in Quebec, Canada. Int J Health Policy Manag. 2024;13(1):1–12.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bansback N, Brazier J, Tsuchiya A, Anis A. Using a discrete choice experiment to estimate health state utility values. J Health Econ. 2012;31(1):306–18.CrossRefPubMed Bansback N, Brazier J, Tsuchiya A, Anis A. Using a discrete choice experiment to estimate health state utility values. J Health Econ. 2012;31(1):306–18.CrossRefPubMed
21.
Zurück zum Zitat Daroudi R, Zeraati H, Poder TG, Norman R, Olyaeemanesh A, Sari AA, Ameri H. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration. Qual Life Res. 2024;33(7):1853–63.CrossRefPubMed Daroudi R, Zeraati H, Poder TG, Norman R, Olyaeemanesh A, Sari AA, Ameri H. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration. Qual Life Res. 2024;33(7):1853–63.CrossRefPubMed
22.
Zurück zum Zitat Mulhern BJ, Bansback N, Norman R, Brazier J, Group S-DIP. Valuing the SF-6Dv2 classification system in the United Kingdom using a discrete-choice experiment with duration. Med Care. 2020;58(6):566–73.CrossRefPubMed Mulhern BJ, Bansback N, Norman R, Brazier J, Group S-DIP. Valuing the SF-6Dv2 classification system in the United Kingdom using a discrete-choice experiment with duration. Med Care. 2020;58(6):566–73.CrossRefPubMed
23.
Zurück zum Zitat Xie S, Wu J, Xie F. Whose time trade-off should be used? anchoring discrete choice experiment latent utilities in health state valuation. Value Health. 2023;26(9):1405–12. Xie S, Wu J, Xie F. Whose time trade-off should be used? anchoring discrete choice experiment latent utilities in health state valuation. Value Health. 2023;26(9):1405–12.
24.
Zurück zum Zitat Kouakou CR, He J, Poder TG. Estimating the monetary value of a quality-adjusted life-year in Quebec. Eur J Health Econ. 2024;25(5):787–811. Kouakou CR, He J, Poder TG. Estimating the monetary value of a quality-adjusted life-year in Quebec. Eur J Health Econ. 2024;25(5):787–811.
26.
Zurück zum Zitat Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
27.
Zurück zum Zitat Wang L, Poder TG. A systematic review of SF-6D health state valuation studies. J Med Econ. 2023;26(1):584–93.CrossRefPubMed Wang L, Poder TG. A systematic review of SF-6D health state valuation studies. J Med Econ. 2023;26(1):584–93.CrossRefPubMed
Metadaten
Titel
Assessing the Direct Impact of Death on Discrete Choice Experiment Utilities
verfasst von
Hossein Ameri
Thomas G. Poder
Publikationsdatum
06.12.2024
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-024-00929-6